Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Qiagen to buy PG Biotech for $14.5 million
PG Biotech is a leading manufacturer of polymerase chain reaction (PCR)-based molecular diagnostic kits in China. Qiagen hopes the acquisition will expand its position as a provider of
PG Biotech is a leading manufacturer of polymerase chain reaction (PCR)-based molecular diagnostic kits in China. Qiagen hopes the acquisition will expand its position as a provider of
Transplantation of insulin-producing pancreatic beta-cells shows great promise as a treatment for type 1 diabetes, but development of this therapy has been hampered by a severe shortage of
The biopharmaceutical company hopes that women in particular will seek treatments earlier if they have the choice of an oral drug that is less arduous to use than
Funds were awarded under the National Institute of Allergy and Infectious Diseases (NIAID) Biodefense Challenge Grants program, which encourages private industry to work with academic investigators in order
Insulin-dependent diabetes is caused by the destruction of the insulin-producing cells in the pancreas, called islet cells, by auto-reactive T cells. The loss of insulin results in an
Under the agreement, Adolor is responsible for conducting clinical trials, managing the approval process and, upon receipt of marketing approval, commercializing the product in North America. “If LidoPAIN
Immunologists have previously used synthetic peptides to stimulate immunity to viruses and cancers where naturally-occurring peptides were failing. However, many of these peptides have been unstable and degraded
The four US patents provide additional protection for systemic delivery of drugs in specific therapeutic areas, namely analgesics, hormones, anti-Parkinson’s agents and anti-emetics. These are “continuation in part”
The submission seeks approval for two strengths of the drug and is based on 27 phase I, II and III trials designed to assess the efficacy and safety
Sevoflurane is an inhaled anesthetic originally developed by Baxter in the 1970s. The company licensed the patents for making the product in the 1980s to Maruishi Pharmaceutical, which